Companies › Allogene Therapeutics
5 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| cemacabtagene ansegedleucel allogeneic CAR T cell therapy targeting CD19 | CD19 | Phase 2 | Large B-cell Lymphoma | Dec 2027 |
| ALLO-329 Allogeneic dual CAR T-cell therapy targeting CD19 and CD70 | CD19, CD70 | Phase 1 | Systemic Lupus Erythematosus (With and Without Nephritis) | Feb 2028 |
| ALLO-501A Anti-CD19 allogeneic CAR T cell therapy | CD19 | Phase 1 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Feb 2029 |
| ALLO-316 Allogeneic CAR T cell therapy targeting CD70 | CD70 | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Jan 2030 |
| ALLO-647 Monoclonal antibody targeting CD52 | CD52 | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Jan 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06500273 | cemacabtagene ansegedleucel | Phase 2 | Large B-cell Lymphoma | Oncology | Dec 2027 |
| NCT07085104 | ALLO-329 | Phase 1 | Systemic Lupus Erythematosus (With and Without Nephritis) | Immunology | Feb 2028 |
| NCT04416984 | ALLO-501A | Phase 1 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Oncology | Feb 2029 |
| NCT04696731 | ALLO-316 | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Oncology | Jan 2030 |
| NCT04696731 | ALLO-647 | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Oncology | Jan 2030 |
Cash and short-term investments of $389m on 2026-09-30; operating cash outflow about $109m a year; runway about 43 months at that burn, to Apr 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Erasca Takara Bio Bicara Therapeutics Fate Therapeutics OncoVerity
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.